Kintai, Studying The Enteric Signaling Pathway, Is Looking For Partners
Emerging Company Profile: The start-up, funded by Flagship Pioneering, is developing small molecules across multiple therapeutic areas, based on a discovery platform exploring the microbiome, gut immune system and enteric nervous system.
You may also be interested in...
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.